Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers

Pharmacogenomics

Volumn 14, Issue 10, 2013, Pages 1203-1214

  López Rodríguez, Rosario ^a,b   Cabaleiro, Teresa ^c   Ochoa, Dolores ^c   Román, Manuel ^c   Borobia, Alberto M ^d   Carcas, Antonio J ^d   Ayuso, Carmen ^b,e   Novalbos, Jesús ^c   Abad Santos, Francisco ^b,c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

adverse reaction; genetic marker; olanzapine; quetiapine; risperidone

Indexed keywords

CATECHOL METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DRD2 PROTEIN, HUMAN; HTT PROTEIN, HUMAN; NERVE PROTEIN; NEUROLEPTIC AGENT; PHARMACOLOGICAL BIOMARKER;

5HT2A GENE; ABDOMINAL PAIN; ANHEDONIA; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMT GENE; CONCENTRATION LOSS; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DNA POLYMORPHISM; DRD2 GENE; DRD3 GENE; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSMENORRHEA; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GRIN2B GENE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INCIDENCE; INSOMNIA; IRRITABILITY; LEG CRAMP; LIBIDO; MALAISE; MALE; MENTAL DISEASE; MRD1 GENE; NEUROLOGIC DISEASE; NIGHTMARE; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); POLYDIPSIA; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCL6A4 GENE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; UROGENITAL TRACT DISEASE; VOMITING; WEIGHT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; ADULT; ADVERSE DRUG REACTION; CLINICAL TRIAL; GENETICS; PATHOLOGY; PHASE 1 CLINICAL TRIAL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOMARKERS, PHARMACOLOGICAL; DIBENZOTHIAZEPINES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; MALE; NERVE TISSUE PROTEINS; RECEPTORS, DOPAMINE D2; RISPERIDONE;

EID: 84880454055     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.106     Document Type: Article

References (52)

1. Kane JM. Addressing nonresponse in schizophrenia. J. Clin. Psychiatry 73(2), e07 (2012).
2. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005). (Pubitemid 41345943)
3. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16(1), 23-45 (2002). (Pubitemid 34151336)
4. Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J. Clin. Psychiatry 67(7), 1093-1103 (2006). (Pubitemid 44230881)
5. Maher AR, Maglione M, Bagley S et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA 306(12), 1359-1369 (2011).
6. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade of research. Mol. Psychiatry 12(8), 707-747 (2007). (Pubitemid 47172693)
7. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003). (Pubitemid 36159890)
8. Wilke RA, Dolan ME. Genetics and variable drug response. JAMA 306(3), 306-307 (2011).
9. Arranz MJ, Rivera M, Munro JC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25(11), 933-969 (2011).
10. Ryu S, Oh S, Cho EY et al. Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B(8), 949-959 (2011).
11. Lopez-Rodriguez R, Roman M, Novalbos J, Pelegrina ML, Ochoa D, Abad-Santos F. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J. Clin. Psychopharmacol. 31(5), 555-562 (2011).
12. Novalbos J, Lopez-Rodriguez R, Roman M, Gallego-Sandin S, Ochoa D, Abad-Santos F. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J. Clin. Psychopharmacol. 30(5), 504-511 (2010).
13. Penas-LLedo EM, Dorado P, Pacheco R, Gonzalez I, Lerena A. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 10(7), 1111-1120 (2009).
14. Gonzalez I, Penas-Lledo EM, Perez B, Dorado P, Alvarez M, LLerena A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9(7), 833-840 (2008).
15. Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin. Pharmacol. Ther. 21(3), 247-254 (1977). (Pubitemid 8064243)
16. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J. Psychiatr. Res. 42(2), 89-97 (2008). (Pubitemid 350061252)
17. Kocabas NA. Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD). CNS Neurol. Disord. Drug Targets 11(3), 264-272 (2012).
18. Kuzman MR, Medved V, Bozina N, Grubisin J, Jovanovic N, Sertic J. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J. 11(1), 35-44 (2010).
19. Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog. Neuropsychopharmacol. Biol. Psychiatry 29(6), 1062-1073 (2005). (Pubitemid 41080133)
20. Allen NC, Bagade S, McQueen MB et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: The SzGene database. Nat. Genet. 40(7), 827-834 (2008). (Pubitemid 351913655)
21. Aragam N, Wang KS, Anderson JL, Liu X. TMPRSS9 and GRIN2B are associated with neuroticism: A genome-wide association study in a European sample. J. Mol. Neurosci. 50(2), 250-256 (2012).
22. Almoguera B, Riveiro-Alvarez R, Gomez-Dominguez B et al. Evaluating a newly developed pharmacogenetic array: Screening in a Spanish population. Pharmacogenomics 11(11), 1619-1625 (2010).
23. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 21(11), 911-936 (2007). (Pubitemid 47557106)
24. Komossa K, Rummel-Kluge C, Schwarz S et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (1), CD006626 (2011).
25. Deng C, Lian J, Pai N, Huang XF. Reducing olanzapine-induced weight gain side effect by using betahistine: A study in the rat model. J. Psychopharmacol. 26(9), 1271-1279 (2012).
26. Deng C, Weston-Green K, Huang XF. The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gaiñ Prog. Neuropsychopharmacol. Biol. Psychiatry 34(1), 1-4 (2010).
27. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: New pathological insights and therapies. Annu. Rev. Med. 58, 49-61 (2007). (Pubitemid 46706500)
28. Kroeze WK, Hufeisen SJ, Popadak BA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3), 519-526 (2003).
29. Houston JP, Kohler J, Bishop JR et al. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J. Clin. Psychiatry 73(8), 1077-1086 (2012).
30. Boonleang J, Pipatrattanaseree W, Tanthana C, Mahatthanatrakul W. Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. Clin. Ther. 32(10), 1842-1853 (2011).
31. Markowitz JS, Devane CL, Boulton DW, Liston HL, Risch SC. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. J. Clin. Pharmacol. 42(1), 104-106 (2002). (Pubitemid 34038376)
32. Sathirakul K, Chan C, Teng L, Bergstrom RF, Yeo KP, Wise SD. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br. J. Clin. Pharmacol. 56(2), 184-187 (2003). (Pubitemid 36981433)
33. Seeman MV. Secondary effects of antipsychotics: Women at greater risk than men. Schizophr. Bull. 35(5), 937-948 (2009).
34. Hedenmalm K, Guzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J. Clin. Psychopharmacol. 26(2), 192-197 (2006). (Pubitemid 43740346)
35. Koning JP, Vehof J, Burger H et al. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl.) 219(3), 727-736 (2011).
36. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-analysis of pharmacogenetic interactions. Mol. Psychiatry 13(5), 544-556 (2008). (Pubitemid 351556033)
37. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol. Psychiatry 41(7), 827-829 (1997).
38. Zai CC, De Luca V, Hwang RW et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol. Psychiatry 12(9), 794-795 (2007). (Pubitemid 47347796)
39. Yasui-Furukori N, Saito M, Tsuchimine S et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(6), 1491-1495 (2008).
40. Young RM, Lawford BR, Barnes M et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2.*A1 allele. Br. J. Psychiatry 185, 147-151 (2004). (Pubitemid 39061458)
41. Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7(6), 479-484 (1997). (Pubitemid 27517576)
42. Dolzan V, Plesnicar BK, Serretti A et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B(6), 809-815 (2007). (Pubitemid 47417211)
43. Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry 61(11), 1163-1169 (2004). (Pubitemid 39463418)
44. Perlis RH, Mischoulon D, Smoller JW et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 54(9), 879-883 (2003). (Pubitemid 37311349)
45. Biernacka JM, McElroy SL, Crow S et al. Pharmacogenomics of antidepressant induced mania: A review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J. Affect. Disord. 136(1-2), e21-e29 (2011).
46. Lesch KP, Bengel D, Heils A et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292), 1527-1531 (1996). (Pubitemid 26403928)
47. Mortensen OV, Thomassen M, Larsen MB, Whittemore SR, Wiborg O. Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res. Mol. Brain Res. 68(1-2), 141-148 (1999).
48. Hu XZ, Rush AJ, Charney D et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64(7), 783-792 (2007). (Pubitemid 47026374)
49. Zalsman G, Huang YY, Oquendo MA et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am. J. Psychiatry 163(9), 1588-1593 (2006). (Pubitemid 44465760)
50. Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr. Genet. 11(4), 219-222 (2001). (Pubitemid 34102298)
51. Cabaleiro T, Lopez-Rodriguez R, Ochoa D, Roman M, Novalbos J, Abad-Santos F. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum. Psychopharmacol. 28(3), 205-214 (2013).
52. Holden M, Deng S, Wojnowski L, Kulle B. GSEA-SNP: Applying gene set enrichment analysis to SNP data from genome-wide association studies. Bioinformatics 24(23), 2784-2785 (2008). (Pubitemid 352722627) Universitario de La Princesa